At Virupaksha, delivering excellence in pharmaceutical manufacturing is not just a goal; it’s an unwavering commitment to quality and innovation. Renowned for producing high-purity Fluconazole, our facilities are meticulously crafted to meet the stringent standards set by WHO-GMP, ensuring that every batch reflects our dedication to global health. Our adherence to ISO 9001 guarantees that we maintain a robust quality management system, while ISO 14001 highlights our commitment to environmentally sustainable practices throughout the production process.
This meticulous attention to detail is particularly crucial given Fluconazole’s vital role in treating cryptococcal meningitis—a life-threatening condition affecting immunocompromised patients worldwide. With each step of our manufacturing process steeped in scientific rigor and ethical responsibility, Virupaksha stands at the forefront of pharmaceutical excellence, dedicated to making a profound impact on patient care globally.
Other Latest News
- Why pharma manufacturers are still investing in Europe February 4, 2026 4:31 pm Pharmaceutical Technology Undeterred by tariffs and global competition, pharma manufacturers are seeing an opportunity in Europe and continuing to invest accordingly. Europe’s share of international pharma manufacturing has declined drastically in the past 25 years. European active …
- Top stocks in news: Bajaj Housing, UPL, PB Fintech, Indus Towers, RailTel, Zen Tech, IRB February 3, 2026 2:35 am Business Today Indian benchmark indices ended higher on Monday after the budget day carnage as the policy continuity with a clear emphasis on growth and fiscal prudence has helped reinforce confidence. BSE Sensex surged 943.52 points, or 1.17 per cent, to settle at 81, …
- Capstone LLC Releases 2026 Healthcare Outlook: Policy Shifts and Market Restructuring to Reshape Provider, Payor, and Pharma Dynamics January 31, 2026 7:01 pm WFMZ - Pennsylvania WASHINGTON, Jan. 31, 2026 /PRNewswire/ -- Capstone LLC, a leading policy analysis and investment research firm, has released its healthcare sector preview for 2026, identifying key policy and regulatory developments expected to drive investment …
- Fierce Pharma Asia—AZ's $15B China investment; Boehringer, Simcere's IBD deal; Daiichi's ADC growth push January 30, 2026 3:55 pm Fierce Pharma AstraZeneca made a big commitment to China as CEO Pascal Soriot joined British Prime Minister Keir Starmer on a trip to the country. Boehringer Ingelheim secured a preclinical inflammatory bowel disease bispecific from Simcere. Daiichi Sankyo's U.S. …
- Silicon-Driven Health: AI Digital Twins And The US$1 Billion Pharma Deal January 29, 2026 11:00 pm Investing News Network As massive capital flows into the life science sector, two distinct, and potentially opposing, strategic directions have emerged. While NVIDIA (NASDAQ:NVDA) is expanding its healthcare presence through a US$1 billion deal with Eli Lilly and Company (NYSE: …
- <![CDATA[Halo Pharma Becomes Dedicated North American Drug Product CDMO]]> January 29, 2026 7:32 pm Pharmaceutical Technology Halo Pharma has emerged as a standalone drug product contract development and manufacturing organization (CDMO) based out of North America.¹ The news comes as a result of SK Capital Partners entering into a definitive agreement to divest the active …
- Business News | Sigachi Industries Aims to Increase Revenue Potential by INR 250 Cr Commencing from Q427 January 23, 2026 8:33 am Latestly VMPL Hyderabad (Telangana) [India], January 23: Sigachi Industries Ltd. (NSE: SIGACHI; BSE: 543389), a leading Indian pharmaceutical company, today announced a significant milestone in its research and development pipeline with the successful advancement …
- Pharma Data Integrity Auditor Masterclass Training Course: Department-Level Audit Strategies, Critical Findings, and Regulatory Expectations (Online Event: Apr 22nd - Apr 23rd, 2026) - ResearchAndMarkets.com January 15, 2026 9:04 pm Voice of Alexandria - Minnesota DUBLIN--(BUSINESS WIRE)--Jan 15, 2026-- The "Data Integrity Auditor Masterclass Training Course (Apr 22nd - Apr 23rd, 2026)" training has been added to ResearchAndMarkets.com's offering. Data integrity has received more attention than ever …
- Budget 2026: Healthcare, Insurance And Pharma Seek Push On Preventive Care, Tax Relief, Local Push January 14, 2026 9:46 am News18 Last Updated:January 14, 2026, 13:21 IST Healthcare industry players say the sector will closely watch policy measures aimed at strengthening infrastructure, technology adoption and supply-side resilience. Budget 2026 will be tabled on Sunday, February 01. …
- Trump administration ties pricing deals with another nine pharma companies December 22, 2025 12:37 pm Pharmaceutical Technology Nine big pharma companies have reached agreements with the Trump administration to lower prices for certain drugs in the US under the President’s Most Favored Nation (MFN) policy. Amgen, Bristol Myers Squibb (BMS), Boehringer Ingelheim, Genentech, Gilead …
- Flow chemistry, AI, and NMR: A next-gen approach to scalable API production December 17, 2025 12:33 pm Medical News In this interview, News Medical speaks with Guillaume Bentzinger, Project Manager at Novalix; Luis Carrillo, Managing Director at De Dietrich France; Philippe Robin CEO of Alysophil; and Alejandro Bara-Estaún, Solution Product Manager at Bruker about how …
- Top stocks in news: Wakefit, Wipro, BEL, Paytm, Corona Remedies, Dr Reddy's, Auro Pharma December 15, 2025 3:09 am Business Today Indian benchmark indices ended higher on Friday amid optimism around liquidity after the US Fed's rate cut even as the rupee hit news lows and FIIs outflows continued. BSE Sensex surged 449.53 points, or 0.53 per cent, to settle at 85,267.66, while NSE …
- Business News | India's CRDMO Sector Set to Grow at 13% CAGR, Market Share Seen Rising to 5% by 2029: Report December 11, 2025 6:11 am Latestly New Delhi [India], December 11 (ANI): India's Contract Research, Development and Manufacturing Organisation (CRDMO) sector is poised for accelerated growth, supported by surging global pharma outsourcing, rising demand for complex modalities, and …
- <![CDATA[Trends and Challenges Impacting Highly Potent API Development]]> December 8, 2025 10:59 pm Pharmaceutical Technology Demand for highly potent active pharmaceutical ingredients (HPAPIs) remains high in the face of a continued focus by the pharmaceutical industry on the oncology space, targeted therapies, and precision medicine. Consequently, HPAPIs account for a growing …
- Top stocks in news: Eternal, IndiGo, ICICI Bank, ONGC, Lenskart, Ola, Whirlpool, MTAR Tech December 8, 2025 3:49 am Business Today Indian benchmark indices ended with big gains on Friday after the rate cuts by RBI, along with supportive liquidity measures. Traders will be looking at the US Fed's policy outcome due later this week. BSE Sensex rose 447.05 points, or 0.52 per cent, …
- What matters in the API market as 2026 approaches December 2, 2025 11:57 am Pharmaceutical Technology The active pharmaceutical ingredient (API) landscape is shifting. Companies are rethinking their sourcing strategies, upgrading their technological capabilities, and relying more heavily on CDMOs that can deliver resilience, specialism, and speed. In 2024, …
- Shift To Biosimilars, $5 Bn Nutraceutical Boom: Pharma Sector's Next BIG Leap November 26, 2025 4:17 pm Zee News India’s pharmaceutical industry is preparing for a transformative leap as it strengthens its global foothold with USD 30 billion in exports, a rapid shift toward biosimilars and complex generics, and a booming USD 5 billion nutraceutical market. From …
- AstraZeneca Shares Leap 9% as Pharma Giant Secures Breakthrough Cancer Drug Approval in UK Market November 24, 2025 10:11 am ABC Money Anglo-Swedish pharmaceutical giant AstraZeneca plc sparked a frenzy in healthcare shares today, with shares soaring more than 9% to 12,500 pence on the London Stock Exchange after the regulators gave the green light to its star oncology treatment, which it …
- The 93rd API China 2025: A Gateway to China’s Pharmaceutical Industry Innovation and Global Collaboration November 19, 2025 6:30 pm Biospectrum Asia The 93rd API China 2025: A Gateway to China’s Pharmaceutical Industry Innovation and Global Collaboration November 20, 2025 | Thursday | News Innovation and Partnership Take Centre Stage at the 93rd Edition of API China in Chongqing Pharma Professionals …
- API China 2025: Pioneering Innovation, Collaboration, and Growth in the Global Pharmaceutical Supply Chain November 19, 2025 6:30 pm Biospectrum Asia API China 2025: Pioneering Innovation, Collaboration, and Growth in the Global Pharmaceutical Supply Chain November 20, 2025 | Thursday | News | By Hithaishi C Bhaskar API China 2025 reinforcing its position as a central hub for the global pharmaceutical …
- US vulnerable to China's API dominance, says report November 19, 2025 11:38 am pharmaphorum China has such a dominant position in active pharmaceutical ingredient (API) production that there is a risk it could "weaponise" access, according to a new congressional report. The document, from the US-China Economic and Security Review …
- Quid Pro Quo? How Washington and Big Pharma Are Partnering Up to Lower Drug Prices and Abate Tariffs in Return for U.S. Investments November 18, 2025 3:11 am Healthcare Packaging Key Takeaways: · In return for their investment in U.S. manufacturing, the administration would drop a proposed 100% tariffs on branded and patented drugs imported to the U.S. · Trump’s push for most-favored-nation aims to lower the price of …
- Shilpa Pharma Lifesciences 憑藉卓越可持續發展實踐 榮獲 EcoVadis 金獎 November 17, 2025 8:37 pm Macau Business 印度賴久爾 2025年11月17日 /美通社/ — Shilpa Medicare Limited（孟買證券交易所：530549）（印度國家證券交易所股票代碼：SHILPAMED）旗下的重要子公司 Shilpa Pharma Lifesciences Limited 宣佈，榮獲全球最受信賴的商業可持續發展評級機構 EcoVadis 頒發享負盛名的金獎。 該公司獲得 82/100 的優異評分，在 EcoVadis 評估的全球超過 130,000 間企業中，位列第 98 …
- Eagle Forum of Alabama, API cheer U.S. Senate closing ‘dangerous intoxicating hemp’ loophole November 12, 2025 1:27 pm 1819 News - Alabama On Tuesday, Alabama conservative groups applauded the U.S. Senate for including a ban on "intoxicating hemp-derived drugs," such as Delta-8 THC, in legislation to reopen the federal government. The legislation closed a "loophole" …
- Top stocks in news: Lenskart, Bajaj Auto, HAL, Trent, Nykaa, Nalco, Swiggy, Lupin, Medanta November 10, 2025 4:35 am Business Today Indian benchmark indices settled mildly lower on Friday as they staged a strong rebound from day's low amid muted domestic and global cues. BSE Sensex retreated 94.73 points, or 0.11 per cent, to settle at 83,216.28, while NSE's Nifty50 tumbled 17. …
- The Analyst Verdict: Amphastar Pharma In The Eyes Of 4 Experts November 7, 2025 1:05 pm Benzinga Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Amphastar Pharma (NASDAQ:AMPH) in the last three months. The table below summarizes their recent ratings, showcasing the evolving sentiments within the …
- <![CDATA[Pharma Pulse: Cholesterol Imbalance Tied to Depression Risk, Lilly Acquires Aderum Biotechnologies, and Cambrex Expands API Manufacturing]]> October 27, 2025 12:47 pm Pharmaceutical Commerce Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and in today’s episode, we’re exploring new …
- China’s Pharma Leverage Is ‘Nuclear Option’ in US Trade Talks October 24, 2025 10:06 am Yahoo Finance (Bloomberg) -- President Xi Jinping’s stranglehold on rare earths will give China unprecedented leverage to win concessions from the US during talks this weekend in Kuala Lumpur. Sitting in Beijing’s reserve is control over an even more vital supply chain: …
- Choice bullish on Laurus Labs: Pharma stock slips 4%; brokerage sees 19% upside potential October 24, 2025 7:44 am Business Today Shares of Laurus Labs dropped as much as 3.7 per cent on Friday to touch a day’s low of Rs 901.85 on the BSE, declining from its previous close of Rs 936.75. At last check, the scrip was trading 2.86 per cent lower at Rs 910. Brokerage Choice Institutional …
- Merck KGaA to mothball operations at Ireland API plant by end of 2028 October 23, 2025 1:20 am Fierce Pharma As a newly christened manufacturing facility comes online in one part of Ireland, Merck KGaA plans to turn out the lights at another roughly three hours north. Merck KGaA plans to discontinue operations at its production plant in Arklow, Ireland, “by the …